The primary objective of this study is to determine the overall response rate to erlotinib in patients with polycythemia vera (PV). Response rate will be assessed by improvement in the complete blood count, ultrasound of the spleen, and JAK2 molecular status. It is purposed in this study to explore a possible molecular targeting of the driving mechanism of PV.
Name: Erlotinib
Description: Grade 3 or grade 4 toxicities as measured by CTCAE v3.0
Measure: Incidence of Toxicities Time: First assessment at day 15, subsequent assessments at 28 day intervals for an average of 1 yearAllocation: N/A
Single Group Assignment
There is one SNP
Phase II Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera. --- V617F ---
Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera The primary objective of this study is to determine the overall response rate to erlotinib in patients with polycythemia vera (PV). --- V617F ---